

14<sup>th</sup> November 2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001  <b>Scrip Code: BSE – AJANTPHARM 532331</b>	National Stock Exchange of India Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051  <b>Scrip Code: NSE AJANTPHARM EQ</b>
---	---

**Subject: - Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI  
(Listing Obligations and Disclosure Requirements), 2015**

Dear Sir / Madam,

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of Related Party Transactions in the prescribed format for the half year ended 30<sup>th</sup> September 2022.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

**Gaurang Shah**  
*VP – Legal & Company Secretary*

Encl.: a/a







Related party transactions											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
Sr No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments		Notes	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure		Secured/ unsecured
43	Ajanta Pharma Limited		Tanya Agrawal		Daughter of Managing Director	Any other transaction	Short Term Employee benefits		Transactions are carried out on arms length basis and in ordinary course of business	0.05	0.00	0.00									
44	Ajanta Pharma Limited		Tanya Agrawal		Daughter of Managing Director	Any other transaction	Post Employment Benefits		N.A.	0.00	0.00	0.00									
45	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Any other transaction	Short Term Employee benefits		N.A.	6.17	0.00	0.00									
46	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Any other transaction	Post Employment Benefits		N.A.	0.14	0.00	0.00									
47	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Any other transaction	Commission to Directors		N.A.	2.63	0.00	0.00									
48	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Any other transaction	Commission payable		N.A.	0.00	5.25	2.63									
49	Ajanta Pharma Limited		Ajanta Pharma (Mauritius) Ltd		Subsidiary	Investment			N.A.	0.00	9.44	9.44									
50	Ajanta Pharma Limited		Ajanta Pharma Philippines Inc.		Subsidiary	Dividend received			N.A.	35.14	0.00	0.00									
51	Ajanta Pharma Limited		Samta Puroshattam Agrawal Memorial Foundation		Promoter group is able to exercise significant control over this entity	Any other transaction	Corporate Social Responsibility expense	5.75	Transactions are carried out on arms length basis and in ordinary course of business	2.92	0.00	0.00									
Total value of transaction during the reporting period										406.02											

Note: Amount approved by Audit Committee is for the entire financial year